The tweet was deleted by the author.
But we saved everything 🙂.
Castle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma.
The study involved multiple centers and provides peer-reviewed evidence supporting the clinical use of the DecisionDx-SCC test for improving risk classification in these patients.
View post on X Loading...
Castle Biosciences has recently outlined new strategies in advanced diagnostics and data innovation at the Future Biotech Expo 2026. The company also began dual listing on Nasdaq Texas while maintaining its primary listing on the Nasdaq Global Market under the ticker CSTL, according to a recent announcement. These developments reflect Castle Biosciences' ongoing efforts to expand its product offerings and market presence.